Full-year results for Sensyne Health announced

 1 min | By Gill Oliver
 |  | Oct 8th 2019

Oxford-based healthcare tech company Sensyne Health plc has announced its audited full-year results for the 12 months ended April 30, 2019.

Spending on research and development reached £9.512m, up from £2.742m the previous year. The AIM-listed company reported total revenue of £0.136m, up from £0.081m, while adjusted operating loss from continuing operations was £11.513m, versus £6.222m for 2018.

go deeper

Sensyne Health describes itself as a ‘docking station’ for the analysis of anonymised NHS patient data on behalf of commercial partners under strict ethical control.

It links the pharmaceutical sector with clinicians, with the aim of aiding pharma companies to transform insights gathered from clinical AI into better-targeted drugs.

In August, Sensyne signed a two-year collaboration agreement with multi-national pharma giant Bayer, to accelerate the clinical development of new treatments for cardiovascular disease.

Chief executive Lord Paul Drayson comments: “I am pleased to report strong progress in our first full year reporting period as a public company, achieving a number of important milestones.”

About the Author

Gill Oliver

Gill Oliver is a professionally trained journalist who’s written for The New Statesman, The Bureau for Investigative Journalism, The Daily Mail’s business section This is Money, The Press Association, The Huffington Post plus a host of national magazines, news agencies and trade and industry journals. She’s also spent nine years reporting on the Oxfordshire business and tech scene for The Oxford Times and The Oxford Mail.

Subscribe to our newsletter